VIRIOS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3549 USD | -4.75% |
|
-13.75% | -38.28% |
| 05-09 | Transcript : Virios Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| 05-09 | Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 58.82 | 42.61 | 4.326 | 11.07 | 6.835 | - | - |
| Enterprise Value (EV) 1 | 58.82 | 42.61 | 4.326 | 11.07 | 6.835 | 6.835 | 6.835 |
| P/E ratio | -3.58 x | -2.66 x | -0.21 x | -2.05 x | -2.09 x | -1.18 x | -0.72 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 7,832 | 8,330 | 18,330 | 19,258 | 19,258 | - | - |
| Reference price 2 | 7.510 | 5.115 | 0.2360 | 0.5750 | 0.3549 | 0.3549 | 0.3549 |
| Announcement Date | 18/03/21 | 17/03/22 | 14/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -15.64 | -12.32 | -5.447 | -4.745 | -13.01 | -17.49 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -15.96 | -12.25 | -5.296 | -4.745 | -12.96 | -17.49 |
| Net income 1 | -10.35 | -15.96 | -12.25 | -5.296 | -4.745 | -12.96 | -17.49 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -2.100 | -1.920 | -1.110 | -0.2800 | -0.1700 | -0.3000 | -0.4900 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 18/03/21 | 17/03/22 | 14/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | -4.111 | -4.188 | -3.961 | -3.672 | -2.592 | -2.09 | -1.557 | -1.477 | -1.274 | -1.138 | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | -4.11 | -4.511 | -3.96 | -3.667 | -2.576 | -2.045 | -1.517 | -1.441 | -1.235 | -1.103 | - | - | - | - |
| Net income | -4.11 | -4.511 | -3.96 | -3.667 | -2.576 | -2.045 | -1.517 | -1.441 | -1.235 | -1.103 | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.4900 | -0.5400 | -0.4800 | -0.4400 | -0.2800 | -0.1100 | -0.0800 | -0.0800 | -0.0600 | -0.0600 | -0.0700 | -0.0400 | -0.0400 | -0.0500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 17/03/22 | 12/05/22 | 11/08/22 | 14/11/22 | 14/03/23 | 12/05/23 | 10/08/23 | 13/11/23 | 29/02/24 | 09/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 18/03/21 | 17/03/22 | 14/03/23 | 29/02/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3549
USD
Average target price
2.2
USD
Spread / Average Target
+519.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.28% | 6.83M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- VIRI Stock
- Financials Virios Therapeutics, Inc.
